10-Q: Yijia Group Corp. Reports Significant Revenue Increase in Q3 2025 Driven by Healthcare Products

Yijia Group Corp. reports a substantial revenue increase in Q3 2025, primarily driven by the commencement of its healthcare products segment.

Summary

• Yijia Group Corp. filed its 10-Q for the quarter ended January 31, 2025.
• The company reported a net revenue of $308,318 for the three months ended January 31, 2025, compared to $26,100 for the same period in 2024.
• For the nine months ended January 31, 2025, the company's net revenue was $708,913, a significant increase from $26,100 in the corresponding period of 2024.
• The increase in revenue is primarily attributed to the commencement of the healthcare products segment.
• The company reported a net income of $72,978 for the three months ended January 31, 2025, compared to a net income of $5,948 for the same period in 2024.
• For the nine months ended January 31, 2025, the company reported a net income of $50,414, compared to a net loss of $27,054 for the same period in 2024.
• The company's cash balance as of January 31, 2025, was $405,173, compared to $593,036 as of April 30, 2024.
• The company's total current assets as of January 31, 2025, were $1,321,141, compared to $1,192,858 as of April 30, 2024.
• The company's total current liabilities as of January 31, 2025, were $212,789, compared to $136,920 as of April 30, 2024.
• The company identified material weaknesses in its internal controls related to the lack of a functioning audit committee and ineffective controls over period-end financial disclosure and reporting processes.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the significant revenue and income growth. However, the identified internal control weaknesses and decreased cash balance temper the overall outlook.

Positives

• The company experienced a significant increase in revenue due to the commencement of the healthcare products segment.
• The company achieved net income for both the three and nine months ended January 31, 2025, compared to the same periods in 2024.
• The company's total assets increased from $1,192,858 as of April 30, 2024, to $1,321,141 as of January 31, 2025.

Negatives

• The company's cash balance decreased from $593,036 as of April 30, 2024, to $405,173 as of January 31, 2025.
• The company identified material weaknesses in its internal controls related to the lack of a functioning audit committee and ineffective controls over period-end financial disclosure and reporting processes.
• The gross profit margin decreased from 100% to 61% for the three months ended January 31, 2025, compared to the same period in 2024.

Risks

• The company's limited operating history and need for additional capital pose risks to its future performance.
• The company's reliance on a small number of major customers and vendors creates concentration risks.
• The identified material weaknesses in internal controls could lead to material misstatements in future financial statements.

Future Outlook

The company continues to look for other opportunities which could potentially increase the profits of the Company in 2025.

Industry Context

The company's entry into the healthcare products segment reflects a broader trend of companies diversifying their revenue streams to capitalize on growing demand for health-related products and services.

Comparison to Industry Standards

• It is difficult to compare Yijia Group Corp. to industry standards without knowing the specific sub-industry within healthcare products and consulting services.
• However, the significant revenue growth suggests a successful entry into the healthcare products market, although the decrease in gross profit margin warrants further investigation.
• Comparable companies in the healthcare products distribution space include McKesson Corporation and Cardinal Health, but their scale and scope are significantly different.
• In the consulting services sector, companies like Accenture and Deloitte are industry benchmarks, but Yijia's consulting services appear to be more focused on management, business, accounting, and finance.

Related Party Transactions

• In June 2024, Ms. Lu, Chief Executive Officer and Director of the Company, loaned the Company an aggregate principal amount of $50,000, which bears interest at a monthly rate of 0.5% and becomes payable upon maturity on December 3, 2024.
• In August 2024, Ms. Lu, Chief Executive Officer and Director of the Company, loaned the Company an aggregate principal amount of $50,000, which bears interest at a monthly rate of 0.5% and becomes payable upon maturity on April 13, 2025.
• In September 2024, Ms. Lu, Chief Executive Officer and Director of the Company, loaned the Company an aggregate principal amount of $25,000, which bears interest at a monthly rate of 0.5% and becomes payable upon maturity on January 4, 2025.
• On January 8, 2024, the Company granted 5,000 shares of common stocks issuable per month in total of 60,000 shares of common stock to the Chief Financial Officer Steve Niu at fair value of $0.05 per share, subject to vesting condition in completion of one year of service.
• On January 1 2025, the Company renewed employment contract with Mr. Niu, which Mr. Niu shall continue serve as Chief Financial Officer with monthly compensation of $2,000 for his service.

Stakeholder Impact

• Shareholders may view the increased revenue and net income positively.
• Employees may benefit from the company's growth and potential future expansion.
• Customers may have access to a wider range of healthcare products and consulting services.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company as a more creditworthy borrower due to its improved financial performance.

Key Dates